Aldeyra Therapeutics, Inc. , a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated and metabolic diseases, today announced that the company will.
Aldeyra Therapeutics, Inc (NASDAQ:ALDX – Get Free Report) major shareholder Perceptive Advisors Llc acquired 37,712 shares of the firm’s stock in a transaction that occurred on Friday, April 5th. The shares were bought at an average price of $4.74 per share, with a total value of $178,754.88. Following the acquisition, the insider now directly owns […]
Aldeyra Therapeutics, Inc (NASDAQ:ALDX – Get Free Report) major shareholder Perceptive Advisors Llc acquired 37,712 shares of the firm’s stock in a transaction that occurred on Friday, April 5th. The shares were bought at an average price of $4.74 per share, with a total value of $178,754.88. Following the acquisition, the insider now directly owns […]